FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Opinion On Shares Of Group 1 Automotive, Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by $10 to $375, based on a 2027 P/E of 7.9x, a slight premium to GPI's 10-year average forward P/E of 7.7x. We lower our adjusted EPS estimates to $41.50 from $44.40 for '26 and to $47.70 from $48.40 for '27. After an uncharacteristically weak earnings release, we are maintaining a Hold on shares of GPI. Heading into the release, GPI's quarterly earnings had beat more than 90% of the time over the past eight years, but a sizeable Q1 miss on disappointing sales cause us to remain at a Hold. However, one silver lining was an improvement in the performance of its U.K. operations. On the positive side, GPI continues to aggressively return cash to shareholders through both dividends and buybacks, retiring 1.7% of total shares outstanding in Q1. The fundamental backdrop remains difficult for auto dealerships, and this quarter marked three straight bottom-line misses for GPI, which had previously held one of the best earnings track records in auto retail.

Related Articles

Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Labcorp Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $300 from $325, 16.6x our 2026 EPS estimate, a premium to LH's three-year historical forward average of 15.3x, supported by our favorable view for health care services, including healthy lab testing volume growth within an environment of high medical utilization, as well as attractive growth prospects given new therapies and aging demographics, in our opinion. We raise our 2026 EPS estimate to $18.03 from $17.90 and raise our 2027 estimate to $19.32 from $19.15. Q1 2026 acquisitions were $202 million, including operations from Crouse Health's Laboratory Alliance of Central New York, while management expressed confidence in the upcoming deal pipeline during the Q1 earnings conference call. Acquisitions totaled $582 million during 2025. LH anticipates a 30 bps headwind for diagnostics volumes in 2026 due to the recent expiration of ACA enhanced premium tax credits, which we expect to cause a meaningful drop in ACA exchange insurance coverage.

$LH
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Cardinal Health Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $225 from $260, 19.3x our FY 27 EPS estimate (up $0.24 to $11.66; FY 26 estimate up to $10.75 from $10.28), a premium to CAH's one- and three-year historical forward averages of 17.2x and 14.7x, respectively, to reflect our favorable outlook for pharmaceutical distributors.

$CAH
Research

Research Alert: CFRA Maintains Buy Opinion On Shares Of Blue Owl Capital Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We reduce our 12-month target price by $5 to $15, applying a more conservative equity risk premium and a forward P/E of 15.0x compared to the three-year historical average on 2026 earnings at 19.4x. We reduce our 2026 distributable earnings (DE) by $0.05 to $0.95 and 2027's by $0.10 to $1.05. We have seen negative investor sentiment on private credit, OWL's redemptions from retail investor, and direct loan exposure to technology and professional services businesses potentially hurt by AI disruption. However, fundamentals in private credit markets and specifically direct loans remain stable, with no signs of systemic risk or any indicators that loan delinquencies are accelerating. OWL has a diversified portfolio evident with direct loans representing only 37% of total AUM at $315B. In Q1 2026, fundraising rose to $44.4B Y/Y compared to $29.4B a year ago, and Private Credit was up $20.8B, +40% Y/Y (47% of total fundraising). Private Wealth fundraising was only $2.9B, mostly in Real Assets and Private Credit.

$OWL